Bone Therapeutics Invests in Cell Therapy Manufacturing Facility
Production facility expected to be fully operational in 2015
Bone Therapeutics, an international biopharmaceutical company focused on cell therapy products for the treatment of bone diseases, announces that it has secured its future manufacturing requirements, allowing it to produce its unique bone cell therapy products on a commercial scale.
Bone Therapeutics has made an investment in Skeletal Cell Therapy Support S.A (SCTS), alongside the Walloon region and private investors, to fund the €10 million construction of a new manufacturing facility based in the Gosselies Scientific Park near Brussels, Belgium. The financing of the building cost is fully secured in equal parts in equity, loans from ING and BNP Paribas Fortis and subsidies from the Walloon Region. Bone Therapeutics is now a 49.9% shareholder in SCTS. Skeletal Cell Therapy Support S.A will manage the construction and will run the site once operational.
This investment will allow Bone Therapeutics to manufacture its lead product PREOB®, an autologous bone cell therapy product currently in Phase III clinical trials for the treatment of osteonecrosis, under GMP conditions.
The construction of the new facility will also provide SCTS customers with state-of-the-art facilities tailored to meet the specific demands of the cell therapy industry and deliver long-term operational and financial efficiencies, with an improved manufacturing process at an increased scale. The completed production unit will initially include six class B production cells across 1.950m2 and will be able to produce up to 5.000 batches per annum at full capacity. In addition, 1.300m2 will be dedicated to quality control and research activities.
Upon completion of construction in 2015, Bone Therapeutics will be headquartered at the facility.
Other news from the department manufacturing
